MBX Butterfly Strategy
MBX (MBX Biosciences, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX (MBX Biosciences, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.26B, a beta of 0.78 versus the broader market, a 52-week range of 9.43-45.85, average daily share volume of 533K, a public-listing history dating back to 2000, approximately 43 full-time employees. These structural characteristics shape how MBX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.78 places MBX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a butterfly on MBX?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current MBX snapshot
As of May 15, 2026, spot at $32.59, ATM IV 108.70%, IV rank 10.28%, expected move 31.16%. The butterfly on MBX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this butterfly structure on MBX specifically: MBX IV at 108.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a MBX butterfly, with a market-implied 1-standard-deviation move of approximately 31.16% (roughly $10.16 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MBX expiries trade a higher absolute premium for lower per-day decay. Position sizing on MBX should anchor to the underlying notional of $32.59 per share and to the trader's directional view on MBX stock.
MBX butterfly setup
The MBX butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MBX near $32.59, the first option leg uses a $30.96 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MBX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MBX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $30.96 | N/A |
| Sell 2 | Call | $32.59 | N/A |
| Buy 1 | Call | $34.22 | N/A |
MBX butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
MBX butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on MBX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on MBX
Butterflies on MBX are pinning bets - traders use them when they expect MBX to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
MBX thesis for this butterfly
The market-implied 1-standard-deviation range for MBX extends from approximately $22.43 on the downside to $42.75 on the upside. A MBX long call butterfly is a pinning play: it pays maximum at the middle strike if MBX settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current MBX IV rank near 10.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MBX at 108.70%. As a Healthcare name, MBX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MBX-specific events.
MBX butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MBX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MBX alongside the broader basket even when MBX-specific fundamentals are unchanged. Always rebuild the position from current MBX chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on MBX?
- A butterfly on MBX is the butterfly strategy applied to MBX (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With MBX stock trading near $32.59, the strikes shown on this page are snapped to the nearest listed MBX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MBX butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the MBX butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 108.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MBX butterfly?
- The breakeven for the MBX butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MBX market-implied 1-standard-deviation expected move is approximately 31.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on MBX?
- Butterflies on MBX are pinning bets - traders use them when they expect MBX to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current MBX implied volatility affect this butterfly?
- MBX ATM IV is at 108.70% with IV rank near 10.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.